Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Retained Earnings: 2021-2024

Historic Retained Earnings for ARS Pharmaceuticals (SPRY) over the last 4 years, with Dec 2024 value amounting to -$123.3 million.

  • ARS Pharmaceuticals' Retained Earnings fell 46.20% to -$253.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$253.3 million, marking a year-over-year decrease of 46.20%. This contributed to the annual value of -$123.3 million for FY2024, which is 6.09% up from last year.
  • As of FY2024, ARS Pharmaceuticals' Retained Earnings stood at -$123.3 million, which was up 6.09% from -$131.3 million recorded in FY2023.
  • ARS Pharmaceuticals' 5-year Retained Earnings high stood at -$42.3 million for FY2021, and its period low was -$131.3 million during FY2023.
  • Moreover, its 3-year median value for Retained Earnings was -$123.3 million (2024), whereas its average is -$110.5 million.
  • Its Retained Earnings has fluctuated over the past 5 years, first tumbled by 82.08% in 2022, then grew by 6.09% in 2024.
  • Yearly analysis of 4 years shows ARS Pharmaceuticals' Retained Earnings stood at -$42.3 million in 2021, then crashed by 82.08% to -$76.9 million in 2022, then plummeted by 70.66% to -$131.3 million in 2023, then increased by 6.09% to -$123.3 million in 2024.